ARTICLE IN ACADEMIC JOURNALS
| NO | DETAILS OF ARTICLE IN ACADEMIC JOURNALS |
|---|---|
| 1. |
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
2023
Author(s) : Maznah Binti Dahlui, Fatiha Hana Shabaruddin Source :
FRONTIERS IN PUBLIC HEALTH
DOI :
10.3389/fpubh.2023.1114560
|
| 2. |
Integrating real-world data in cost-effectiveness analysis of universal HLA-B15:02 screening in Malaysia
2023
Author(s) : Ng Ching Ching, Maznah Binti Dahlui, Lim Kheng Seang, Fatiha Hana Shabaruddin, Lai Siew Mei Pauline, Fong Si Lei Source :
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
DOI :
10.1111/bcp.15818
|
| 3. |
The Burden of Out-of-Pocket Expenditure Related to Gynaecological Cancer in Malaysia
2022
Author(s) : Maznah Binti Dahlui, Fatiha Hana Shabaruddin Source :
HEALTHCARE
DOI :
10.3390/healthcare10102099
|
| 4. |
Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications
2021
Author(s) : Rosmawati Binti Mohamed, Maznah Binti Dahlui, Lim Soo Kun, Fatiha Hana Shabaruddin, Gan Chye Chung Source :
NEPHROLOGY
DOI :
10.1111/nep.13862
|
| 5. |
Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications
2021
Author(s) : Fatiha Hana Shabaruddin Source :
Nephrology
DOI :
https://doi.org/10.1111/nep.13862
|
| 6. |
Assessing adherence and persistence to non-vitamin K antagonist oral anticoagulants (NOACs) among patients with atrial fibrillation in tertiary-care referral centers in Malaysia
2020
Author(s) : Fatiha Hana Shabaruddin Source :
Journal of Pharmacy and BioAllied Sciences
|
| 7. |
Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method.
2020
Author(s) : Fatiha Hana Shabaruddin Source :
Substance Use and Misuse
DOI :
https://doi.org/10.1080/10826084.2019.1708943
|
| 8. |
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.
2019
Author(s) : Fatiha Hana Shabaruddin Source :
Public Health Genomics
|
| 9. |
Hepatitis C elimination by 2030 in Malaysia: an achievable goal?
2019
Author(s) : Fatiha Hana Shabaruddin, Rosmawati Binti Mohamed Source :
Journal of Virus Eradication
|
| 10. |
A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs.
2019
Author(s) : Rosmawati Binti Mohamed, Fatiha Hana Shabaruddin Source :
Value in Health Regional Issues
|
| 11. |
Risk of upper gastrointestinal adverse events in Malaysian rheumatic patients on long-term non-steroidal anti-inflammatory drugs
2018
Author(s) : Sanjiv A/l K. Mahadeva, Fatiha Hana Shabaruddin Source :
International Journal of Clinical Rheumatology
DOI :
10.4172/1758-4272.1000182
|
| 12. |
Projections of the Healthcare Costs and Disease Burden due to
Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-204
2018
Author(s) : Fatiha Hana Shabaruddin Source :
Appl Health Econ Health Policy
|
| 13. |
Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country. Southeast Asian Journal of Tropical Medicine and Public Health 49(5): z (ISI-cited publication)
2018
Author(s) : Fatiha Hana Shabaruddin Source :
Southeast Asian Journal of Tropical Medicine and Public Health
|
| 14. |
Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients compared to Routine Clinical Surveillance? The case of an upper middle-income country in Asia
2018
Author(s) : Fatiha Hana Shabaruddin, Woo Yin Ling Source :
Applied Health Economics and Health Policy
|
| 15. |
Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs
2018
Author(s) : Fatiha Hana Shabaruddin Source :
International Journal of Rheumatic Diseases
|
| 16. |
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine
2018
Source :
PUBLIC HEALTH GENOMICS
|
| 17. |
Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040
2018
Author(s) : Rosmawati Binti Mohamed, Adeeba Binti Kamarulzaman, Maznah Binti Dahlui, Fatiha Hana Shabaruddin Source :
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
|
| 18. |
Is Universal HLA-B*15:02 Screening a Cost-Effective Option in an Ethnically-Diverse Population? A Case Study of Malaysia.
2017
Source :
British Journal of Dermatology
DOI :
10.1111/bjd.15498
|
| 19. |
Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. PLoS One 10(6):e0128091. doi:10.1371/journal.pone.0128091
2015
Author(s) : Fatiha Hana Shabaruddin |
| 20. |
Economic evaluations of personalized medicine: existing challenges and current developments
2015
Author(s) : Fatiha Hana Shabaruddin Source :
Pharmacogenomics and Personalized Medicine
|
| 21. |
Chapter 18 Evaluating the Cost-Effectiveness of Pharmacogenomics in Clinical Practice in the Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy
2014
Author(s) : Fatiha Hana Shabaruddin Source :
the Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy (edited by Dr. Ioannis S. Vizirianakis, Aristotle University of Thessaloniki, Greece) Publisher: Pan Stanford Publishing Pte. Ltd. ISBN 978-981-4411-19-6
|
| 22. |
Shabaruddin FH, Chen LC, Elliott RA, Payne K (2013) A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics 31(4):277-288
2013
Author(s) : Fatiha Hana Shabaruddin |
| 23. |
A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events
2013
Author(s) : Fatiha Hana Shabaruddin Source :
Pharmacoeconomics
|
| 24. |
Cost-effectiveness analysis in pharmacogenomics
2010
Author(s) : Fatiha Hana Shabaruddin Source :
Pharmacogenomics
|
| 25. |
Reply: Guesstimates are not good enough for
determining
what is happening in routine care.
2010
Author(s) : Fatiha Hana Shabaruddin Source :
British Journal of Cancer
|
| 26. |
Reply: Guesstimates are not good enough for determining what is happening in routine care
2010
Author(s) : Fatiha Hana Shabaruddin Source :
British Journal of Cancer
|
| 27. |
Understanding chemotherapy treatment pathways of
advanced colorectal cancer patients to inform an
economic evaluation in the United Kingdom.
2010
Author(s) : Fatiha Hana Shabaruddin |
RESEARCH COLLABORATOR
| GRANT | PROGRESS | STATUS |
|---|